Neoadjuvant Therapy in Hepatopancreatobiliary Malignancies: Current Trends and Future Directions
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 15 February 2026 | Viewed by 694
Special Issue Editor
Interests: digestive oncology; immunotherapy; angiogenesis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue, “Neoadjuvant Therapy in Hepatopancreatobiliary Malignancies: Current Trends and Future Directions”, will explore the evolving landscape of neoadjuvant treatments for hepatopancreatobiliary cancers, including hepatocellular carcinoma, pancreatic cancer, and cholangiocarcinoma. Neoadjuvant therapy, encompassing chemotherapy, radiotherapy, immunotherapy, and targeted approaches, plays a critical role in improving surgical outcomes and survival rates in these challenging malignancies. For this Special Issue, we invite the submission of original research articles, reviews, and clinical studies that address current advancements, novel therapeutic strategies, and the molecular mechanisms underlying treatment responses. Contributions should focus on the latest clinical trials, treatment protocols, biomarkers for predicting efficacy, and emerging personalized treatment approaches. The goal is to provide a comprehensive update on both established and experimental therapies, highlighting future directions in neoadjuvant treatment in these cancers.
Dr. Daniela Cornelia Lazăr
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neoadjuvant therapy
- hepatopancreatobiliary malignancies
- hepatocellular carcinoma
- pancreatic cancer
- cholangiocarcinoma
- chemotherapy
- radiotherapy
- immunotherapy
- targeted therapies
- personalized treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
